Key result
Anti-IL-1 agents reduce pericarditis recurrence by ~73% compared with colchicine.
Why the study?
Do colchicine and anti-interleukin-1 agents reduce pericarditis recurrence in patients with recurrent pericarditis?
Meta-Analysis
Do colchicine and anti-interleukin-1 agents reduce pericarditis recurrence in patients with recurrent pericarditis?
Both colchicine and anti-interleukin-1 agents effectively reduce recurrent pericarditis, with anti-IL-1 agents demonstrating superior efficacy to colchicine but potentially more non-serious adverse events.
Answers are grounded in this paper and cite their sources.
Favors colchicine first for recurrent pericarditis due to better tolerability; confirms efficacy of both therapies in Level 1 evidence.
BACKGROUND: The management of recurrent pericarditis includes colchicine and anti-interleukin-1 agents, given the limited efficacy and adverse effects of NSAIDs and corticosteroids. We conducted a pairwise and network meta-analysis to evaluate the efficacy and safety of colchicine and anti-interleukin-1 agents in recurrent pericarditis. METHODS: We conducted a comprehensive search on various databases to retrieve relevant randomized controlled trials. Pairwise meta-analyses were performed in R using the exact Mantel-Haenszel method. We also performed a network meta-analysis with a colchicine group as the comparator. RESULTS: A total of 6 randomized controlled trials were included in the meta-analysis. The risk of pericarditis recurrence was significantly decreased by colchicine (risk ratio [RR], 0.46 [95% CI, 0.37-0.58]) and anti-interleukin-1 agents (RR, 0.12 [95% CI, 0.03-0.54]) compared with placebo or standard therapy. Colchicine significantly decreased the risk of treatment failure (RR, 0.42 [95% CI, 0.31-0.57]) and pericarditis-related rehospitalization (RR, 0.26 [95% CI, 0.10-0.70]) but did not have a significant impact on the risk of adverse events (RR, 1.06 [95% CI, 0.31-3.62]). Anti-interleukin-1 agents were associated with a significantly increased risk of adverse events (RR, 1.88 [95% CI, 1.60-2.21]). The network meta-analysis showed that anti-interleukin-1 agents were associated with a greater reduction in pericarditis recurrence than colchicine (RR, 0.27 [95% CI, 0.11-0.67]), with no significant difference with respect to adverse events (RR, 1.77 [95% CI, 0.88-3.57]). CONCLUSIONS: Both colchicine and anti-interleukin-1 agents are effective in reducing the risk of recurrent pericarditis. Anti-interleukin-1 agents are associated with more frequent nonserious adverse events, but evidence on serious adverse events remains inconclusive.
No takes yet. Share an insight, caveat, or question.
Ehsan et al. (2025) conducted a meta-analysis in recurrent pericarditis. Anti-interleukin-1 agents vs. Colchicine was evaluated on pericarditis recurrence (RR 0.27, 95% CI 0.11-0.67). Anti-interleukin-1 agents were associated with a greater reduction in pericarditis recurrence than colchicine, with no significant difference in adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: